Free tool
FAERS Monitor: Recorlev
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214133 or its brand name (Recorlev, Levoketoconazole). Reports on generic versions are filed under their own applications.
Reports
756
Serious
438
58% of reports
Hospitalization
195
Death reported
14
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue256
- nausea222
- headache181
- dizziness117
- vomiting105
- diarrhoea94
- pain87
- weight decreased84
- malaise79
- insomnia77
- arthralgia73
- asthenia73
- decreased appetite67
- feeling abnormal66
- abdominal discomfort59
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 49 |
| 2023 | 88 |
| 2024 | 92 |
| 2025 | 145 |
| 2026 | 382 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,403 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| abdominal discomfortSignal | 59 | 9.8 | 7.7 | 460 |
| fatigueSignal | 256 | 9.2 | 8.3 | 1,921 |
| weight decreasedSignal | 84 | 8.4 | 6.8 | 545 |
| insomniaSignal | 77 | 8.0 | 6.5 | 474 |
| headacheSignal | 181 | 8.0 | 7.1 | 1,141 |
| decreased appetiteSignal | 67 | 8.0 | 6.4 | 410 |
| nauseaSignal | 222 | 7.8 | 7.0 | 1,361 |
| feeling abnormalSignal | 66 | 7.7 | 6.1 | 380 |
| dizzinessSignal | 117 | 6.5 | 5.5 | 555 |
| vomitingSignal | 105 | 6.2 | 5.2 | 464 |
| astheniaSignal | 73 | 5.4 | 4.3 | 262 |
| malaiseSignal | 79 | 5.0 | 4.1 | 255 |
| arthralgiaSignal | 73 | 4.9 | 3.9 | 226 |
| diarrhoeaSignal | 94 | 4.1 | 3.4 | 220 |
| painSignal | 87 | 3.9 | 3.2 | 194 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.